These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 30461207)

  • 41. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer.
    Büntzel J; Küttner K; Fröhlich D; Glatzel M
    Ann Oncol; 1998 May; 9(5):505-9. PubMed ID: 9653491
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In regard to Münter et Al. Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without amifostine. (Int j radiat oncol biol phys 2007;67:651-659).
    Messerschmidt GL; Oleka N
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1651-2; author reply 1652. PubMed ID: 18035221
    [No Abstract]   [Full Text] [Related]  

  • 43. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer.
    Wasserman T; Mackowiak JI; Brizel DM; Oster W; Zhang J; Peeples PJ; Sauer R
    Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1035-9. PubMed ID: 11072160
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Protection of salivary function by concomitant pilocarpine during radiotherapy: a double-blind, randomized, placebo-controlled study.
    Burlage FR; Roesink JM; Kampinga HH; Coppes RP; Terhaard C; Langendijk JA; van Luijk P; Stokman MA; Vissink A
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):14-22. PubMed ID: 17869018
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients.
    Rades D; Fehlauer F; Bajrovic A; Mahlmann B; Richter E; Alberti W
    Radiother Oncol; 2004 Mar; 70(3):261-4. PubMed ID: 15064010
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group Study.
    Poulsen MG; Denham JW; Peters LJ; Lamb DS; Spry NA; Hindley A; Krawitz H; Hamilton C; Keller J; Tripcony L; Walker Q
    Radiother Oncol; 2001 Aug; 60(2):113-22. PubMed ID: 11439206
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Amifostine reduces radiation therapy-induced dry mouth in head and neck cancer patients.
    Oncology (Williston Park); 2004 Sep; 18(10):1314, 1316. PubMed ID: 15526835
    [No Abstract]   [Full Text] [Related]  

  • 48. [Current status of prevention and management of radiation-induced xerostomia].
    Ma DY; Qiu WL; Zhang CP
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2010 Feb; 45(2):121-3. PubMed ID: 20368009
    [No Abstract]   [Full Text] [Related]  

  • 49. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
    Movsas B; Scott C; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Smith C; Axelrod R; Sarna L; Wasserman T; Byhardt R
    J Clin Oncol; 2005 Apr; 23(10):2145-54. PubMed ID: 15800308
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intensity-modulated radiation therapy versus three-dimensional conformal radiotherapy in head and neck squamous cell carcinoma: long-term and mature outcomes of a prospective randomized trial.
    Gupta T; Sinha S; Ghosh-Laskar S; Budrukkar A; Mummudi N; Swain M; Phurailatpam R; Prabhash K; Agarwal JP
    Radiat Oncol; 2020 Sep; 15(1):218. PubMed ID: 32938468
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oral candidiasis in head and neck cancer patients receiving radiotherapy with amifostine cytoprotection.
    Nicolatou-Galitis O; Sotiropoulou-Lontou A; Velegraki A; Pissakas G; Kolitsi G; Kyprianou K; Kouloulias V; Papanikolaou I; Yiotakis I; Dardoufas K
    Oral Oncol; 2003 Jun; 39(4):397-401. PubMed ID: 12676261
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Amifostine: a radioprotector in locally advanced head and neck tumors.
    Wagner W; Prott FJ; Schonekas KG
    Oncol Rep; 1998; 5(5):1255-7. PubMed ID: 9683846
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.
    Culy CR; Spencer CM
    Drugs; 2001; 61(5):641-84. PubMed ID: 11368288
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prospective randomized controlled trial to compare 3-dimensional conformal radiotherapy to intensity-modulated radiotherapy in head and neck squamous cell carcinoma: Long-term results.
    Ghosh-Laskar S; Yathiraj PH; Dutta D; Rangarajan V; Purandare N; Gupta T; Budrukkar A; Murthy V; Kannan S; Agarwal JP
    Head Neck; 2016 Apr; 38 Suppl 1():E1481-7. PubMed ID: 26561342
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer.
    Antonadou D; Coliarakis N; Synodinou M; Athanassiou H; Kouveli A; Verigos C; Georgakopoulos G; Panoussaki K; Karageorgis P; Throuvalas N;
    Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):915-22. PubMed ID: 11704311
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
    Vikram B
    J Clin Oncol; 2001 Feb; 19(4):1233-4. PubMed ID: 11181692
    [No Abstract]   [Full Text] [Related]  

  • 57. Protection of salivary function by intensity-modulated radiation therapy in patients with head and neck cancer.
    Chao KS
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):20-5. PubMed ID: 11917280
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Risk of xerostomia in association with the receipt of radiation therapy in older patients with head and neck cancer.
    Liu CC; Xia R; Guadagnolo A; Cormier JN; Du XL
    Am J Ther; 2011 May; 18(3):206-15. PubMed ID: 20068441
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rationale for integrating high-dose rate intraoperative radiation (HDR-IORT) and postoperative external beam radiation with subcutaneous amifostine for the management of stage III/IV head and neck cancer.
    Hu K; Ship JA; Harrison LB
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):40-8. PubMed ID: 14727239
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Outcome of primary combined radio-chemotherapy in head and neck tumors with simultaneous salivary gland protection by amifostine].
    Schultze J; Kimmig B
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():13-7. PubMed ID: 10584134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.